Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR003 PET Imaging for Viable Myocardium Detection
NCT05885854Phase 2Completed
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XTR003 in ischemic heart disease (IHD), sponsored by Sinotau Pharmaceutical Group. Primary endpoints: Sensitivity of combining XTR003/FDG PET imaging at Day 1 and Specificity of combining XTR003/FDG PET imaging at Day 1. Started Dec 2021; status: completed.
02
Drugs
XTR003
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT05885854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05885854.